IMMU-132-011
13 Dec 2022
Trial Summary
The primary objective of this study is to assess the objective response rate (ORR) of sacituzumab govitecan-hziy in adult participants with metastatic solid tumors.
Acronym:
IMMU-132-011
ACTRN/NCT /ethics:
NCT03964727
Scientific title:
A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Sponsor / Cooperative group:
Gilead Sciences
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2019-10-15 |
| Anticipated End Date | 2023-07-01 |
Participating Hospitals
| Hospital | Lyell McEwin hospital |
|---|---|
| Clinical Trial Coordinator | Andy Phay |
| andy.phay@sa.gov.au | |
| Phone | 08 8282 0833 |
| Principal Investigator | Dr Chris Hocking |
| Recruitment Status | Recruiting |